Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-EBOV monoclonal antibody 5E9 with unique binding site, and application

A technology of monoclonal antibody and antibody light chain, applied in the field of polypeptide

Active Publication Date: 2020-05-12
ACADEMY OF MILITARY MEDICAL SCI
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Although there are currently no approved Ebola virus disease drugs, several experimental anti-Ebola drugs are under investigation, including small interfering RNA, antisense oligonucleotide drugs, nucleotide analogs, antibody drugs Wait

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-EBOV monoclonal antibody 5E9 with unique binding site, and application
  • Anti-EBOV monoclonal antibody 5E9 with unique binding site, and application
  • Anti-EBOV monoclonal antibody 5E9 with unique binding site, and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1. Antibody Preparation

[0031] 1. Blood Sample Collection

[0032] After obtaining informed consent, 5 mL of blood samples were collected 28 days after the second immunization of the recombinant Ebola vaccine clinical trial subjects for subsequent experiments.

[0033] 2. FITC-labeled protein GPdM

[0034] Specific memory B cells need to be sorted by fluorescently labeled antigens. The method of FITC-labeled truncated antigen protein GPdM is as follows:

[0035] 1) Fluorescein Isothiocyanate_FITC (SIGMA, F4274) was dissolved in DMSO at a concentration of 20 mg / mL.

[0036] 2) Take 100 μL of GPdM (3.3 mg / mL), add buffer (pH9.6 carbonate buffer) to 400 μL.

[0037] 3) Add 8 μL FITC to the GPdM solution, and incubate at 4° C. in the dark for 3 hours.

[0038] 4) Use a 50kD centrifugal concentrator tube to replace the solution with PBS until the filtrate is transparent and colorless. Wrap the labeled protein in tinfoil and store at 4°C until use.

[0039] 3....

Embodiment 2

[0119] Example 2.ELISA detection of antibody binding activity

[0120] 1) The day before the experiment, 96-well enzyme-linked plates were coated with 1 μg / mL of EBOV GP, BDBV GP, SUDV GP and RESTV GP, 100 μL per well. Put the coated ELISA plate in a humid box overnight at 4°C.

[0121] 2) Wash 5 times with a plate washer on the day of the experiment.

[0122] 3) Add 100 μL of blocking solution to each well and let stand at room temperature for 1 hour.

[0123] 4) Wash the plates 5 times in a plate washer.

[0124] 5) Add 150 μL of 5E9 monoclonal antibody at a concentration of 10 μg / mL to the first well, and add 100 μL of diluent to the remaining wells. Aspirate 50 μL from the first well and add to the second well, and so on, dilute the solution in a 1:3 gradient to a final volume of 100 μL in each well. Let stand at room temperature for 1 hour.

[0125] 6) Wash the plates 5 times in a plate washer.

[0126] 7) Dilute the HPR-labeled goat anti-human IgG secondary antibod...

Embodiment 3

[0131] Embodiment 3. Pseudovirus neutralization experiment evaluates 5E9 neutralization activity

[0132] The neutralizing activity of 5E9 was evaluated in vitro by the EBOV pseudovirus packaged with the HIV backbone. The evaluation method is as follows:

[0133] 1) Dilute the 5E9 monoclonal antibody with DMEM medium, add 75 μL of antibody diluent with a concentration of 100 μg / mL to the first well of a 96-well cell culture plate, and add 50 μL of DMEM medium to the remaining wells.

[0134] 2) Pipette 25 μL of liquid from the first well into the second well, mix well, and so on, dilute at a ratio of 1:3, and the final volume of each well is 50 μL.

[0135] 3) Dilute the pseudovirus 1:5 with DMEM medium (control the fluorescein reading in the control well between 20,000 and 100,000), add to each antibody well, 50 μL per well. Mix well and incubate at 37°C for 1h.

[0136] 4) 293T cell count, 2×10 5cells / mL, add 100 μL to each well.

[0137] 5) Put the 96-well cell culture...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a monoclonal antibody 5E9 against an Ebola virus glycoprotein (GP)1 subunit. The antibody has a unique CDR region, and has good binding activity with EBOV GP, and the EC50 value is 0.006 [mu]g / mL. Compared with a control antibody, the 5E9 can effectively neutralize EBOV pseudo-viruses in vitro, the neutralizing activity of the 5E9 is increased with the increase of the antibody concentration, and the antibody can realize 100% protection of cells infected with the EBOV pseudo-viruses at a concentration of 1 [mu]g / mL. The 5E9 also has good neutralizing activity to EBOV invitro, and can be used as a candidate therapeutic drug for Ebola virus diseases. A binding epitope of the 5E9 is located at 95th-190th amino acids of a GP antigen, and the binding epitope of the 5E9 is different from that of neutralizing antibodies in the prior art, so that the 5E9 has the potential to form a cocktail combination therapy with other neutralizing antibodies.

Description

technical field [0001] The invention discloses an antibody and belongs to the technical field of polypeptides. Background technique [0002] Ebola virus (EBOV) can cause acute severe hemorrhagic fever in humans and non-human primates. It is one of the viruses with the highest fatality rate found so far, with a fatality rate as high as 90%. It can be transmitted directly through contact , highly contagious and lethal. The glycoprotein (Glycoprotein, GP) spike on the surface of the Ebola virus envelope almost mediates all steps of the virus entering the cell, so Ebola GP is an important target of virus neutralizing antibodies. The GP gene of Ebola virus is processed into two proteins, one is secreted non-structural GP (secreted glycoprotein, sGP); the other is structural GP. Ebola GP is first synthesized as a polypeptide, and then Furin enzyme digests into GP1 (amino acids 1-501) and GP2 (amino acids 502-676) subunits. The two subunits are connected by disulfide bonds, and t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/10C12N15/13C12N15/85C12N5/10A61K39/42A61P31/14
CPCA61K2039/505A61P31/14C07K16/10C12N5/0636C12N15/85C12N2510/02
Inventor 陈薇范鹏飞于长明迟象阳张冠英侯利华房婷吴诗坡陈旖陈郑珊王美荣刘渝娇
Owner ACADEMY OF MILITARY MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com